Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis.
By L. Moran, M. Misso, R. Wild, R. Norman. Human Reproduction Update, 2010
1,059 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Obstetrics and Gynecology, Reproductive Medicine
View Paper: https://www.semanticscholar.org/paper/2fa33ac258f8f4505f1d1225d787d78f71fb95e8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Obstetrics and Gynecology
In Reproductive Medicine
Citations in the corpus
- 2016 European Guidelines on cardiovascular disease prevention in clinical practice (2017, positive): “PCOS does seem to be associated with a higher risk of developing DM (RR 2–4) [198, 199], sugges t ing that per iodic screening for DM is appropriate.”
- Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. (2012, background): “…(Ehrmann et al., 1999; Legro et al., 1999; Norman et al., 2001; Moran et al., 2010), type 2 diabetes (Ehrmann et al., 1999; Legro et al., 1999; Moran et al., 2010), cardiovascular diseases (Meyer et al., 2005; de Groot et al., 2011) and anxiety and depression (Himelein and Thatcher, 2006;…”
- Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus (2016, background): “The polycystic ovary syndrome (PCOS) describes a female-specific state of androgen excess and hyperinsulinemia related to obesity, T2DM, and higher cardiometabolic risk (72, 73).”
- Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. (2013, positive): “Notably, the similar degree of IR in lean PCOS and overweight control women is consistent with the high risk of diabetes in PCOS, independent of BMI and reinforces the need for screening for glucose intolerance even in lean PCOS women (Meyer et al., 2005; Moran et al., 2010; Teede et al., 2011).”
- National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. (2015, background): “Screening for associated dyslipidemia in PCOS This NLA Expert Panel recommends that all patients with PCOS, regardless of age should undergo initial lipid and diabetes screening, typically with fasting glucose or glycated hemoglobin.(430) The panel also recommends more frequent follow-up screening (”
- Polycystic ovary syndrome: etiology, pathogenesis and diagnosis (2011, background): “5-fold increased prevalence of IGT and a fourfold increased prevalence of T2DM”